Altered microRNome Profiling in Statin-Induced HepG2 Cells: A Pilot Study Identifying Potential new Biomarkers Involved in Lipid-Lowering Treatment
- 25 November 2015
- journal article
- research article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 29 (6) , 509-518
Abstract
Purpose Statins are widely prescribed drugs to manage hypercholesterolemia. Despite they are considered effective lipid-lowering agents, significant inter-individual variability has been reported in relation to drug response. Among the reasons explaining this variation, genetic factors are known to partially contribute. Nonetheless, poor evidence exists regarding epigenetic factors involved. Methods We investigated if atorvastatin can modulate the cholesterol related miR-33 family. Furthermore, we analyzed the microRNA expression profiles in HepG2 cells treated for 24 hours with atorvastatin or simvastatin using a microarray platform. Results Our results indicate that atorvastatin does not influence the expression of the miR-33 family. In addition, microarray examination revealed that atorvastatin modulated thirteen miRs, whilst simvastatin only affected two miRs. All significantly modulated miRs after simvastastin therapy were also modulated by atorvastatin. In addition, four novel miRs with previously unreported functions were identified as statin-modulated. Conclusion We identified several novel miRs affected by statin treatment. Additional research is needed to determine the biological significance of differentially expressed miRs identified in statins-induced HepG2 cells.Keywords
Funding Information
- FONDECYT (1130675)
- CONICYT (24120982)
- FAPESP (2011/21967-1)
- CNPq-Brazil (473485/2012-5)
This publication has 66 references indexed in Scilit:
- Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statinsNature Communications, 2014
- Resistance and intolerance to statinsNutrition, Metabolism and Cardiovascular Diseases, 2014
- Pharmacogenetics of Statins: Achievements, Whole-genome Analyses and Future PerspectivesPharmacogenomics, 2012
- Pitavastatin: evidence for its place in treatment of hypercholesterolemiaCore Evidence, 2010
- Statin Adverse EffectsAmerican Journal of Cardiovascular Drugs, 2008
- Pleiotropic effects of statin therapy: molecular mechanisms and clinical resultsTrends in Molecular Medicine, 2008
- Clinical implications of pharmacogenomics of statin treatmentThe Pharmacogenomics Journal, 2006
- PLEIOTROPIC EFFECTS OF STATINSAnnual Review of Pharmacology and Toxicology, 2005
- Effect of Statins on Risk of Coronary DiseaseJAMA, 1999
- Clinical Outcomes in Statin Treatment TrialsArchives of internal medicine (1960), 1999